Biotech & Health Tech
PepGen's oligo succeeds in Phase 2; Ionis' and ImmunityBio's stocks sag
Plus news about Coherus Oncology, JW Therapeutics and PsiThera. PepGen’s positive mid-stage results in DM1: PepGen said its oligonucleotide therapy PGN-EDODM1 showed positive early signals in a cohort of Phase 2 patients with myotonic dystrophy ...
Plus news about Coherus Oncology, JW Therapeutics and PsiThera. PepGen’s positive mid-stage results in DM1: PepGen said its oligonucleotide therapy PGN-EDODM1 showed positive early signals in a cohort of Phase 2 patients with myotonic dystrophy ...
This is a summary of the story. Read the full article at Endpoints News (Biopharma) ↗